biostudies-literatureUnknown12(14)Jiang Y<b>Rationale:</b> The overall clinical response to FGFR inhibitor (FGFRi) is far from satisfactory in cancer patients stratified by FGFR aberration, the current biomarker in clinical practice. A novel biomarker to evaluate the therapeutic response to FGFRi in a non-invasive and dynamic manner is thus greatly desired. <b>Methods:</b> Six FGFR-aberrant cancer cell lines were used, including four FGFRi-sensitive ones (NCI-H1581, NCI-H716, RT112 and Hep3B) and two FGFRi-resistant ones (primary for NCI-H2444 and acquired for NCI-H1581/AR). Cell viability and tumor xenograft growth analyses were performed to evaluate FGFRi sensitivities, accompanied by corresponding ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake assay. mTOR/PLCγ/MEK-ERK signaling blockade by specific inhibitors orTheranostics6395-6408https://www.ebi.ac.uk/biostudies/studies/S-EPMC9475468biostudies-literature¹⁸F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis.PMC9475468Peng XLiang SZeng QJiang QGao JDing JZhou XAi JHuang RWang LJiang YLin DFeng HGao YWan HZhou Hfalse¹⁸F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis.<b>Rationale:</b> The overall clinical response to FGFR inhibitor (FGFRi) is far from satisfactory in cancer patients stratified by FGFR aberration, the current biomarker in clinical practice. A novel biomarker to evaluate the therapeutic response to FGFRi in a non-invasive and dynamic manner is thus greatly desired. <b>Methods:</b> Six FGFR-aberrant cancer cell lines were used, including four FGFRi-sensitive ones (NCI-H1581, NCI-H716, RT112 and Hep3B) and two FGFRi-resistant ones (primary for NCI-H2444 and acquired for NCI-H1581/AR). Cell viability and tumor xenograft growth analyses were performed to evaluate FGFRi sensitivities, accompanied by corresponding ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake assay. mTOR/PLCγ/MEK-ERK signaling blockade by specific inhibitors or2022-01-01T00:00:00Z20222026-05-28T01:08:17.595Z2025-04-19T22:46:41.419ZS-EPMC94754683616861610.7150/thno.74848